PL3402480T3 - Kompozycje i sposoby dożylnego podawania 2-bromo-1-(3,3-dinitroazetydyn-1-ylo)etanonu - Google Patents

Kompozycje i sposoby dożylnego podawania 2-bromo-1-(3,3-dinitroazetydyn-1-ylo)etanonu

Info

Publication number
PL3402480T3
PL3402480T3 PL17738834T PL17738834T PL3402480T3 PL 3402480 T3 PL3402480 T3 PL 3402480T3 PL 17738834 T PL17738834 T PL 17738834T PL 17738834 T PL17738834 T PL 17738834T PL 3402480 T3 PL3402480 T3 PL 3402480T3
Authority
PL
Poland
Prior art keywords
dinitroazetidin
ethanone
bromo
compositions
methods
Prior art date
Application number
PL17738834T
Other languages
English (en)
Other versions
PL3402480T4 (pl
Inventor
Bryan T. Oronsky
Jan Scicinski
Scott CAROEN
Original Assignee
Epicentrx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx, Inc. filed Critical Epicentrx, Inc.
Publication of PL3402480T4 publication Critical patent/PL3402480T4/pl
Publication of PL3402480T3 publication Critical patent/PL3402480T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
PL17738834T 2016-01-11 2017-01-11 Kompozycje i sposoby dożylnego podawania 2-bromo-1-(3,3-dinitroazetydyn-1-ylo)etanonu PL3402480T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277236P 2016-01-11 2016-01-11
EP17738834.5A EP3402480B1 (en) 2016-01-11 2017-01-11 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
PCT/US2017/012948 WO2017123593A1 (en) 2016-01-11 2017-01-11 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

Publications (2)

Publication Number Publication Date
PL3402480T4 PL3402480T4 (pl) 2021-11-22
PL3402480T3 true PL3402480T3 (pl) 2021-11-22

Family

ID=59311661

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17738834T PL3402480T3 (pl) 2016-01-11 2017-01-11 Kompozycje i sposoby dożylnego podawania 2-bromo-1-(3,3-dinitroazetydyn-1-ylo)etanonu

Country Status (15)

Country Link
US (1) US11576895B2 (pl)
EP (1) EP3402480B1 (pl)
JP (1) JP6931004B2 (pl)
KR (1) KR20190040931A (pl)
CN (1) CN109069420A (pl)
AU (1) AU2017207304B2 (pl)
BR (1) BR112018014027A2 (pl)
CA (1) CA3011103A1 (pl)
DK (1) DK3402480T3 (pl)
EA (1) EA201891606A1 (pl)
ES (1) ES2880482T3 (pl)
MX (1) MX2018008528A (pl)
PL (1) PL3402480T3 (pl)
SG (1) SG11201805942UA (pl)
WO (1) WO2017123593A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
US11576895B2 (en) 2016-01-11 2023-02-14 Epicentrx, Inc Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
JP7332469B2 (ja) 2016-10-14 2023-08-23 エピセントアールエックス，インコーポレイテッド スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物
MX2020000265A (es) 2017-07-07 2020-07-22 Epicentrx Inc Composiciones para la administración parenteral de agentes terapéuticos.
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
MX2022007182A (es) 2019-12-11 2022-07-19 Epicentrx Inc Dispositivos, sistemas y metodos de infusion de medicamentos.
BR112023025535A2 (pt) * 2021-06-09 2024-02-27 Epicentrx Inc Composições de abdnaz cristalinas e métodos para fazer e usar as mesmas
WO2023154480A1 (en) * 2022-02-10 2023-08-17 Epicentrx, Inc. Compositions and methods for treatment of nafld and nash and related dyslipidemias
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2978453A (en) 1956-12-12 1961-04-04 Aerojet General Co 3, 3, 5, 5-tetranitropiperidine
JPS4830376B1 (pl) 1970-12-29 1973-09-19
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5511509A (en) 1978-07-07 1980-01-26 Toomasu Gorudon Robaato Cancer therapy
US4935450A (en) 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
GB8728418D0 (en) 1987-12-04 1988-01-13 Jenkins T C Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5693794A (en) 1988-09-30 1997-12-02 The United States Of America As Represented By The Secretary Of The Navy Caged polynitramine compound
JP2659614B2 (ja) 1990-11-13 1997-09-30 株式会社日立製作所 表示制御装置
TW198712B (pl) 1991-04-17 1993-01-21 Hoffmann La Roche
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ATE168014T1 (de) 1991-11-08 1998-07-15 Somatogen Inc Hämoglobine als arzneimittelabgabesystem
DE4226974C2 (de) 1992-08-14 1994-08-11 Fresenius Ag Verfahren und Vorrichtung zur kontinuierlichen Aufbereitung einer Zellsuspension
US5336784A (en) 1993-06-07 1994-08-09 The Regents Of The University Of California Synthesis of 1,3,3-trinitroazetidine
ATE374607T1 (de) 1994-05-27 2007-10-15 Strakan Int Ltd Zusammensetzung enthaltend stickstoffoxid- donatoren und methode zur behandlung analer krankheiten
JP3142577B2 (ja) 1995-03-14 2001-03-07 シーメンス アクチエンゲゼルシヤフト 着脱自在な精密計量供給ユニット
NZ304009A (en) 1995-03-14 1999-02-25 Siemens Ag Ultrasonic atomizer device with a removable precision dosating unit
US5580988A (en) 1995-05-15 1996-12-03 The United States Of America As Represented By The Secretary Of The Army Substituted azetidines and processes of using them
WO1996036602A1 (en) 1995-05-15 1996-11-21 The United States Of America Adnaz, compositions and processes
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
EP0932591A1 (en) 1996-10-15 1999-08-04 Eastman Chemical Company Explosive formulations
GB9720797D0 (en) 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6056966A (en) 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6391911B1 (en) 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
US20020077276A1 (en) 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
MXPA02010029A (es) 2000-04-10 2003-02-12 Pfizer Prod Inc Compuestos de benzamido-piperidina como antagonistas de la sustancia p.
JP2002069057A (ja) 2000-07-07 2002-03-08 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
DE10111049A1 (de) 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
EP1459724B1 (en) 2001-12-28 2013-11-20 Terumo Kabushiki Kaisha Blood bag system and method of inactivating pathogenic microorganisms
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2005539089A (ja) 2002-07-03 2005-12-22 ニトロメッド インコーポレーティッド ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法
EP1556056A4 (en) 2002-10-07 2008-08-06 Radiorx Inc X-Nitro Compounds, Pharmaceutical Compositions And Their Uses
EP1603933A2 (en) 2003-03-13 2005-12-14 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
JP4430071B2 (ja) 2003-06-25 2010-03-10 ジェ イル ファーマシューティカル カンパニー リミテッド トリサイクリック誘導体またはその薬学的に許容される塩、その製造方法およびそれを含有する薬学的組成物
AU2004257693B8 (en) 2003-07-09 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
GB0326047D0 (en) 2003-11-07 2003-12-10 Univ Sheffield Substance
AU2005282241B2 (en) 2004-09-08 2011-03-03 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
EP1863804A1 (en) 2005-04-01 2007-12-12 Methylgene, Inc. Inhibitors of histone deacetylase
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) * 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
EP1996550A2 (en) 2005-09-27 2008-12-03 Novartis AG Carboxyamine compounds and their use in the treatment of hdac dependent diseases
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US8122281B2 (en) 2007-04-13 2012-02-21 International Business Machines Corporation System and method for dependent failure-aware allocation of distributed data-processing systems
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
WO2012078992A1 (en) * 2010-12-09 2012-06-14 Radiorx, Inc. Organonitro compounds for use in treating non-hodgkin's lymphoma and leukemia, and methods relating thereto
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
WO2013052164A1 (en) * 2011-10-07 2013-04-11 Radiorx, Inc. Organonitro thioether compounds and medical uses thereof
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
US20140220163A1 (en) 2014-02-04 2014-08-07 Hamzeh Soleimani Babadi Powder mixture composition of natural materials for controlling deficiencies in polypeptide alpha and beta hemoglobin chains
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
US11576895B2 (en) 2016-01-11 2023-02-14 Epicentrx, Inc Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
JP7332469B2 (ja) 2016-10-14 2023-08-23 エピセントアールエックス，インコーポレイテッド スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物
MX2020000265A (es) 2017-07-07 2020-07-22 Epicentrx Inc Composiciones para la administración parenteral de agentes terapéuticos.
CA3088875A1 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 for radioprotection
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection

Also Published As

Publication number Publication date
JP6931004B2 (ja) 2021-09-01
EP3402480B1 (en) 2021-03-24
EA201891606A1 (ru) 2019-02-28
CA3011103A1 (en) 2017-07-20
ES2880482T3 (es) 2021-11-24
SG11201805942UA (en) 2018-08-30
AU2017207304A1 (en) 2018-07-26
PL3402480T4 (pl) 2021-11-22
MX2018008528A (es) 2019-05-16
WO2017123593A1 (en) 2017-07-20
KR20190040931A (ko) 2019-04-19
AU2017207304B2 (en) 2022-05-26
US20190307723A1 (en) 2019-10-10
EP3402480A1 (en) 2018-11-21
BR112018014027A2 (pt) 2018-12-11
CN109069420A (zh) 2018-12-21
EP3402480A4 (en) 2019-09-18
US11576895B2 (en) 2023-02-14
JP2019505585A (ja) 2019-02-28
DK3402480T3 (da) 2021-06-28

Similar Documents

Publication Publication Date Title
PL3402480T4 (pl) Kompozycje i sposoby dożylnego podawania 2-bromo-1-(3,3-dinitroazetydyn-1-ylo)etanonu
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
IL289099A (en) Methods for storage of whole blood, and corresponding preparations
DK3312177T3 (da) Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme
GB201720163D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
HK1259372A1 (zh) 治療化合物、其組合物及使用方法
IL266047A (en) Methods and preparations for the treatment of Fabry disease
EP3538189A4 (en) COMPOSITIONS, DEVICES AND METHODS FOR TREATING OPIOID RECEPTOR-MEDIATED STATES
EP3541408A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS
PT3421038T (pt) Compostos de naftiridina, combinações médicas e sua utilização
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
EP3426671A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
IL248773B (en) History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
IL287621A (en) Preparations and methods for treating fungal infections
EP3556402A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS B
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
EP3509575A4 (en) COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE
EP3341006A4 (en) COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
HK1258765A1 (zh) 治療性化合物、組合物和它們的使用方法
GB201714241D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
PT3383402T (pt) Composição farmacêutica compreendendo darunavir e método para a sua preparação